Special Issue

Prevention and Personalized Treatment of Substance Use Disorders

Message from the Guest Editors

Substance use disorders (SUDs) have posed significant public health challenges for many years. Over time, approaches to addressing these disorders have evolved from punitive measures to more compassionate, evidence-based treatments. Recognizing SUDs as chronic, treatable conditions has led to the development of more effective prevention and personalized treatment strategies. This Special Issue seeks to explore innovative methods for preventing SUDs and tailoring treatments to individual needs. This includes evaluating the effectiveness of various prevention programs, early intervention techniques, and personalized treatment plans that consider unique circumstances and history. Current research in this field focuses on combining behavioral therapies with pharmacological treatments, leveraging technology for remote monitoring and support, and creating personalized care plans based on genetic, psychological, and social factors, in addition to neuro-modulation techniques and the impact of community-based interventions. We invite you to contribute original research articles and reviews on all aspects related to the topic at hand.

Guest Editors

Dr. Aleksandra Suchanecka

Dr. Jolanta Chmielowiec

Dr. Kszysztof Chmielowiec

Deadline for manuscript submissions

22 August 2025



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/217402

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

